Trust Formation in University-industry Collaborations in the US Biotechnology Industry

2012 ◽  
Vol 2012 (1) ◽  
pp. 12853
Author(s):  
Ludwig Bstieler ◽  
Martin Hemmert
1992 ◽  
Vol 6 (1) ◽  
pp. 24-29
Author(s):  
Barry Stern

To provide an overview of the US perspective on university–industry cooperation, the author focuses on four areas: (a) the roles of governments, the higher education sector, and industry in continuing technological education; (b) cooperation between higher education and industry in developing technological education; (c) areas in which Europe, Japan, and the USA can fruitfully cooperate in continuing technological education; and (d) major challenges for the short-term future.


1969 ◽  
Vol 12 (4) ◽  
Author(s):  
William Bains

The European biotechnology industry receives less funding, and less funding per company, than the North American industry, especially at the sensitive early stages of company development, and the European industry is substantially smaller in terms of employment, products and capitalisation than the US industry. The cause and effect of this relationship are explored in this paper. It is shown that if the European industry is immature it is because its growth has been slower, most probably because of low investment levels, and that the relatively lower value of biotech companies at initial public offering (IPO) is a result of the lower amount of investment they receive, not a reason for. This suggests that poor investment levels are a primary cause of the small size of European biotech companies and the European industry as a whole, not an effect of it. Investor mistrust and investment mechanisms are plausible reasons for this under-investment.


1969 ◽  
Vol 17 (4) ◽  
Author(s):  
Suzanne Levy

The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States. At this year's annual Biotechnology Industry Organization (BIO) convention, significant discussion revolved around the appropriate interpretation and execution of that mission.The BIO meeting hosted 15 646 participants from across industry, government and the nonprofit sector, focusing on the current state of the biotechnology industry, as well as its challenges in seeking to further improve public welfare. Perhaps partly because this year's meeting was held in Washington, DC – the seat of the federal government and of BIO's headquarters – much attention was paid to the US regulatory environment. In particular, attendees debated the quandary faced every day by the FDA: how to enable access to novel therapies quickly, but only once their safety has been certified.


2012 ◽  
Vol 18 (2) ◽  
Author(s):  
Wesley Daniel Blakeslee

Abstract The biopharmaceutical industry has been undergoing change for a number of years and that change is accelerating.  Larger pharmaceutical companies are acquiring smaller ones, companies are merging, laboratories are being closed, and the number of scientists performing research in the pharmaceutical industry is declining.  Overall, commercial industry, including the biotechnology industry, is becoming more interested in the benefits of collaboration with research institutions.Universities are also changing their view of relationships with industry.  Shrinking federal budgets are causing universities to look at other sources of revenue, including collaborations with industry.  Federal and state governments are also looking closely at the benefits of sponsoring university research, and in particular are seeking to accelerate commercialization of university discoveries not only to obtain the benefit of invested research dollars, but also for economic development and job growth.  Universities, and in particular university technology transfer offices, must understand these changes and adapt to them. This paper discusses the university/industry relationships, and the particular issues important to universities which shape that interface. 


2012 ◽  
Vol 24 (5) ◽  
pp. 453-466 ◽  
Author(s):  
Antonio Messeni Petruzzelli ◽  
Daniele Rotolo ◽  
Vito Albino

2011 ◽  
Vol 40 (9) ◽  
pp. 1188-1199 ◽  
Author(s):  
Christos Kolympiris ◽  
Nicholas Kalaitzandonakes ◽  
Douglas Miller

Sign in / Sign up

Export Citation Format

Share Document